Product Details
| Product Name:
CC4 |
CAS No.:
492-02-4 |
| Supply Ability:
10g |
Release date:
2026/04/22 |
Product Introduction
Bioactivity
| Name | CC4 |
| Description | High affinity and subtype selective α6β2 and α4β2 partial agonist (Ki values are 12 and 26nM for rat α6β2 and α4β2 receptors respectively). Has low affinity for α3β4 and α7 receptors (Ki values are 4.8 and 13 μM for human α3β4 and rat α7 receptors respectively). Stimulates dopamine release from striatal slices in vitro. Attenuates nicotine-induced self-administration and conditional place preference in rats. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : Soluble
|
| Keywords | CC-4 | CC 4 |
| Inhibitors Related | Adiphenine hydrochloride | Levamisole hydrochloride | Ethyl (triphenylphosphoranylidene) acetate | Urethane | Hexamethonium Bromide | Ribavirin | Adenine | Mitotane | Choline chloride | Propoxur | N,N-Dicyclohexylcarbodiimide | Arecoline |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:131410-48-5
$29.00 / 50mg
-
CAS:21187-73-5
$189.00 / 1mg
-
CAS:133161-96-3
$2270.00 / 100μg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$1.00/1KG |
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2024-07-08 |
United States